SAS, a leading company in business intelligence software and services, has launched SAS Drug Development 3.0. Based on the breakthrough capabilities of the SAS9 intelligence platform, SAS drug development provides a centralized repository that allows life sciences firms to analyze their clinical research for regulatory submission and explore new market opportunities, product line extensions and safety issues - all within a controlled and secure collaborative framework designed for life sciences research industries. SAS drug development has been designed to meet federal regulations such as 21 CFR Part 11, good industry practices and sound business practices.

Commenting on the launch, Sudipta K Sen, managing director and CEO, SAS India said "Pharmaceutical companies in India are gearing to find out innovative ways to effectively manage, analyze, and explore massive amounts of complex data, and still minimize their time to market. SAS Drug Development provides an integrated system for managing, analyzing, reporting and reviewing clinical research information. The solution also allows companies to increase revenue potential, enhance the productivity of the clinical research team and improve clinical program investment decisions - all in an environment that facilitates regulatory compliance."